Microsure develops robot-assisted systems for microsurgery, notably the MUSA-3 which is designed in close cooperation with microsurgeons and engineers. The company says MUSA-3 provides precision for microsurgeons and enables interventions that are virtually impossible to perform by hand. Microsure intends to use the new funding to finalize MUSA-3 development for clinical studies, followed by FDA clearance in the USA and CE-marking in Europe. The company is led by CEO Sjaak Deckers and was founded in 2016 by Eindhoven University of Technology and Maastricht University Medical Center. Microsure is based in Eindhoven, The Netherlands, and currently employs over 30 technical professionals. The recent financing strengthens its position to complete clinical validation and regulatory approvals. Microsure develops robot-assisted systems for microsurgery; its leading product MUSA is the first CE-marked and clinically available surgical robot assistant for open microsurgery. MUSA scales down motion and filters tremor to provide steadier manipulation, targeting procedures such as lymphatic-venous anastomosis, distal nerve repair and vascularized tissue transplantation. The company closed a €2.7 million Series B extension to continue the initial clinical roll-out and to further develop improvements to the system. The planned broader market availability of the improved MUSA system is expected in the course of 2022 after Covid-19 related delays. Microsure was founded in 2016 and is based in Eindhoven; it works with clinical and technical advisors including Maastricht University Medical Center+ as a leading clinical partner.

Total raised

$43M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2023